Subretinal macrophages produce classical complement activator C1q leading to the progression of focal retinal degeneration

Haihan Jiao¹, Matt Rutar¹,², Nilisha Fernando¹, Ted Yednock³, Sethu Sankaranarayanan³, Riemke Aggio-Bruce¹, Jan Provis¹,⁴ and Riccardo Natoli¹,⁴*

Abstract

Background: The role of the alternative complement pathway and its mediation by retinal microglia and macrophages, is well-established in the pathogenesis of Age-Related Macular Degeneration (AMD). However, the contribution of the classical complement pathway towards the progression of retinal degenerations is not fully understood, including the role of complement component 1q (C1q) as a critical activator molecule of the classical pathway. Here, we investigated the contribution of C1q to progressive photoreceptor loss and neuroinflammation in retinal degenerations.

Methods: Wild-type (WT), C1qa knockout (C1qa⁻/⁻) and mice treated with a C1q inhibitor (ANX-M1; Annexon Biosciences), were exposed to photo-oxidative damage (PD) and were observed for progressive lesion development. Retinal function was assessed by electroretinography, followed by histological analyses to assess photoreceptor degeneration. Retinal inflammation was investigated through complement activation, macrophage recruitment and inflammasome expression using western blotting, qPCR and immunofluorescence. C1q was localised in human AMD donor retinas using immunohistochemistry.

Results: PD mice had increased levels of C1qa which correlated with increasing photoreceptor cell death and macrophage recruitment. C1qa⁻/⁻ mice did not show any differences in photoreceptor loss or inflammation at 7 days compared to WT, however at 14 days after the onset of damage, C1qa⁻/⁻ retinas displayed less photoreceptor cell death, reduced microglia/macrophage recruitment to the photoreceptor lesion, and higher visual function. C1qa⁻/⁻ mice displayed reduced inflammasome and IL-1β expression in microglia and macrophages in the degenerating retina. Retinal neutralisation of C1q, using an intravitreally-delivered anti-C1q antibody, reduced the progression of retinal degeneration following PD, while systemic delivery had no effect. Finally, retinal C1q was found to be expressed by subretinal microglia/macrophages located in the outer retina of early AMD donor eyes, and in mouse PD retinas.

Conclusions: Our data implicate subretinal macrophages, C1q and the classical pathway in progressive retinal degeneration. We demonstrate a role of local C1q produced by microglia/macrophages as an instigator of inflammasome activation and inflammation. Crucially, we have shown that retinal C1q neutralisation during disease progression may slow retinal atrophy, providing a novel strategy for the treatment of complement-mediated retinal degenerations including AMD.

Keywords: Macrophages, Microglia, Complement system, Classical pathway, C1q, Inflammasome, Retinal degeneration, Photo-oxidative damage, Inflammation, Age-related macular degeneration

* Correspondence: riccardo.natoli@anu.edu.au
¹The John Curtin School of Medical Research, The Australian National University, Building 131, Garran Rd, Canberra, ACT 2601, Australia
²ANU Medical School, The Australian National University, ACT, Canberra, Australia
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

The complement cascade comprises three pathways – classical, mannose-binding lectin, and alternative pathway – all of which converge at the proteolysis of complement component 3 (C3), promoting complement activation and downstream assembly of membrane attack complex (MAC) [1]. Activation of the classical pathway is triggered by complement component 1q (C1q) binding to immune complexes on pathogenic cell surfaces, or atypical activators such as modified lipids, apoptotic cells [2], advanced glycation end products [3] and C-reactive protein [4]. C1q binding promotes the proteolysis of C4, C2, C3 and the downstream activation of the complement cascade, propagating the effector functions of complement, including the lysis of target cells [1].

In neurodegenerative diseases such as Age-Related Macular Degeneration (AMD), complement dysregulation as a consequence of environmental pressures and/or gene mutations, is known to contribute to disease progression [5–7]. AMD is the leading cause of blindness in the Western World, posing a significant economic burden with an annual global cost of 350 billion dollars [8]. Atrophic or “dry” late-stage AMD is characterised by the emergence of geographic atrophy, in which a central retinal lesion in the photoreceptors and retinal pigment epithelium (RPE) develops and progressively expands over time [8]. Genome-wide association studies (GWAS) indicate a link between dysregulation of multiple complement pathways (e.g. C3, C4, C1s, CFI, SERPING1) and the progressive expansion of the macular lesion in geographic atrophy [9]. In addition, histopathological investigations show a range of complement components and factors from all pathways present in drusen of AMD donor eyes (reviewed in [7]). These drusen components are associated with the accrual of activated microglia and infiltrating blood-borne macrophages in the outer retina, which is a well-established feature of AMD pathogenesis [10].

Our previous studies have shown upregulation of a range of complement pathway genes, including Cfb, C3 and Cfh after photo-oxidative retinal degeneration, and demonstrate a critical role for C3-expressing retinal macrophages [11, 12]. However, the contribution of each complement pathway to C3 activation is still largely unknown, impeding the development of effective anti-complement drugs for retinal degenerations [13, 14]. Other investigators have utilised Cfb−/−, C1qa−/− and Mbl−/− mice to demonstrate the involvement of all complement pathways to experimental choroidal neovascularization [15]. Despite strong evidence supporting the involvement of the alternative pathway in retinal degenerations [16], it has been suggested that the alternative pathway is not the only contributor towards retinal degenerations, and that other complement pathways may also facilitate disease progression [15].

Emerging evidence has implicated the classical pathway in AMD, including genetic polymorphisms [17] and an abundance of autoantibodies associated with AMD [18–20]. C1q, the activator molecule of the classical complement pathway, has also been implicated in a number of complement-independent processes including activation of the inflammasome, another key component of the innate immune system [21], and by acting as a bridging molecule between the innate and adaptive immune system [22, 23]. Recently, C1q was found to promote microglial activation and degeneration in retinal ischemia/reperfusion (I/R) injury [24]. However, the role of C1q in the progression of retinal degenerations remains unclear. In this study, we aimed to elucidate the contribution of the classical complement pathway to disease progression, using a model of photo-oxidative damage (PD), in which complement activation by microglia and macrophages is a key feature leading to progressive photoreceptor loss [11]. Our findings illustrate the role of the classical complement pathway in focal retinal degeneration, showing subretinal macrophages as key players in delivering C1q, and that blocking C1q activity during degeneration may be a useful strategy to slow the progression of retinal atrophy.

Methods

Animal experimentation

All procedures were performed in accordance with the Association for Research in Vision and Ophthalmology (ARVO) Statement for Use of Animals in Ophthalmic and Vision Research. The study was approved by the Australian National University Animal Experimentation Ethics Committee (Ethics ID: A2014/56 and A2017/41). Complement component 1, q subcomponent, alpha polypeptide knock out (C1qa−/−) mice were used for this study (C1qa<tm1Mjw>). C57BL/6 J mice were used as wild-type (WT) controls. Animals were born and raised in dim (5 lx) cyclic light conditions in 12:12 h cycle, and housed in individual vented cages (IVCs). Food and water was provided in constant supply and cages changed on a weekly basis. Adult mice aged between postnatal day (P) 60-90 were used for all experiments. Equal numbers of male and female mice were used throughout the study to avoid any gender biases. Animals with no exposure to photo-oxidative damage were used as dim-reared controls.

To induce photo-oxidative damage (PD), mice were housed in Perspex boxes coated with a reflective interior, and exposed to 100Klux of natural white LED for 1, 3, 5 and 7 days, with free access to food and water, as described in our previous methodology [25]. Some animals were recovered in dim light conditions and were
Animals were euthanized with CO₂ prior to tissue collection day 0 (prior to the PD procedure), day 4 (during the type control antibody was administered intraperitoneally 100 mg/kg of ANX-M1 anti-C1q antibody or an IgG isotype control antibody (7.5 μg/μl) was injected into each mouse eye, prior to the PD procedure) and on day 8 (the day after completion of the PD procedure) in order to sustain complement inhibition. Hemolytic assay and retinal assessment were performed at day 12 (N = 10/group) as per our previous publications [11, 27].

**TUNEL and immunohistochemistry**
A terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labelling (TUNEL) assay (Roche Diagnostics, Basel, Switzerland) was used to detect photoreceptor cell death. Retinal cryosections were used for the TUNEL assay according to our previously described protocols, with minor modifications [28, 29]. Sections were counterstained with the DNA-specific dye bisbenzimide (1:10000; Sigma Aldrich, MO, USA) for visualisation of cell nuclei.

To detect and localise specific proteins, immunohistochemistry was performed on retinal cryosections according to previously published methodology, with minor modifications [12, 30]. A list of primary antibodies is provided in Table 1.

**Fluorescence analysis and imaging**
TUNEL⁺ and IBA1⁺ cells were quantified along the full length of retinal cryosection in duplicate sections per animal. For photoreceptor cell death, only TUNEL⁺ cells in the ONL were counted. IBA1⁺ cells in the outer retina (including subretinal space, ONL-RPE) were taken across the cryosection. For each section, number of TUNEL⁺ or IBA1⁺ cells was recorded (superior to inferior) in increments of 0.5 mm across the full length of retinal cryosection. Total cell counts were averaged from at least 2 sections per animal with 6 animals for each experimental group.

To quantify photoreceptor loss in retinal cryosections, the number of rows of photoreceptor nuclei was counted within the retinal lesion site (superior retina, 1 mm away from the optic nerve head). Five measurements were taken per retina in duplicate per animal.

Fluorescence in retinal cryosections was visualised and imaged using a laser-scanning A1⁺ confocal microscope (Nikon, Tokyo, Japan). Images were acquired using NIS-Elements AR software (Nikon). Negative control slides (no primary antibody) were imaged with each immunolabelled slide to determine specificity of staining and set up the threshold for fluorescence intensity for comparison to positively-stained slides. Images were processed and assembled into panels using Photoshop CS6 software (Adobe Systems, CA, USA).

**Fluorescence-activated cell sorting (FACS)**
Mouse retinal microglia and macrophages (CD11b⁺) were isolated using a fluorescence-activated cell sorter (BD FACSAria II; BD Biosciences, NJ, USA), using...
previously described protocols with minor modifications [25, 30, 31]. Mouse retinas were pooled from 2 animals (4 retinas) for each sample. Cells were stained using an anti-mouse CD11b-Phycoerythrin (PE) conjugated antibody (#101207, 1:500; Biolegend, CA, USA). FACS-isolated cells were then used immediately for RNA extraction.

**Quantitative real-time polymerase chain reaction (qPCR)**

RNA extraction and purification was performed on retinas and isolated CD11b+ cells using a combination of TRizol reagent (Thermo Fisher Scientific) and an RNAqueous Total RNA Isolation Kit (Thermo Fisher Scientific) as described in our previous publication [32]. cDNA was prepared from 500 ng of each RNA sample using a Tetro cDNA Synthesis Kit (Bioline Reagents, London, UK) according to the manufacturer’s protocol.

Gene expression changes were measured via qPCR using Taqman hydrolysis probes (listed in Table 2) and Taqman Gene Expression Master Mix (Thermo Fisher Scientific). Each qPCR was run using a QuantStudio 12 K Flex instrument (Thermo Fisher Scientific) at the Biomolecular Resource Facility (JCSMR, ANU). Analysis was performed using the comparative cycle threshold method (ΔΔCt) which was normalised to the expression of Gapdh and Actb reference genes, as established previously [33, 34].

**Western blot**

Retinas were collected into Cellytic M buffer (Sigma-Aldrich) containing a Protease Inhibitor Cocktail (Sigma-Aldrich). Western blotting was performed on retinal protein lysates according to previously described methods with minor modifications [35, 36]. 20 μg of denatured protein was loaded onto a 4-20% Mini-Protean TGX Precast Protein gel (Bio-Rad, CA, USA) followed by semi-dry transfer to a nitrocellulose membrane. A list of primary antibodies used for Western blot are provided in Table 1. A secondary

**Table 1 Primary antibodies used for immunohistochemistry and Western blot**

| Antibody       | Target                                      | Dilution | Source          | Catalog #       |
|----------------|---------------------------------------------|----------|-----------------|-----------------|
| Rabbit α-IBA1  | Ionised calcium binding protein 1           | 1:500    | Wako Chemicals  | 019-19,741      |
| Goat α-IL-1β   | IL-1 beta/ILF2                              | 1:1000   | R&D Systems     | AF-501          |
| Goat α-C3d     | Complement component C3d                    | 1:2000   | R&D Systems     | AF-2655         |
| Rabbit α-C1q   | C1q, clone 4.8                              | 1:400    | Abcam           | AB182451        |
| Rabbit α-C1q   | C1q complement isolated from human plasma   | 1:1000   | Dako            | F0254           |
| Rabbit α-NALP3/NLRP3 | 1-50 amino acids of human NLRP3 | 1:500    | Novus Biologicals | NP82-1244655    |
| Rat α-F4/80    | F4/80 clone A3-1                            | 1:100    | Abcam           | AB6640          |
| Rabbit α-GAPDH | GAPDH                                        | 1:4000   | Sigma Aldrich   | G9545           |

**Table 2 Taqman hydrolysis probes used for qPCR (Thermo Fisher Scientific)**

| Gene symbol | Name                                      | Accession # | Catalog #   |
|-------------|-------------------------------------------|-------------|-------------|
| Actb        | Actin-beta                                | AK078935    | Mm01205647_g1 |
| C1qa        | Component 1, q subcomponent, alpha polypeptide | NM_007572.2 | Mm00432142_m1 |
| C2          | Component 2                                | NM_013484   | Mm00442726_m1 |
| C4          | Component 4                                | NM_011413   | Mm01132415_g1 |
| Casp-1      | Caspase-1                                  | NM_009807   | Mm00438023_m1 |
| Casp-8      | Caspase-8                                  | NM_001080126| Mm01255716_m1 |
| Cfb         | Factor B                                  | NM_001142706| Mm00433918_g1 |
| Cfh         | Factor H                                  | NM_009888   | Mm01299248_m1 |
| Cntf        | Ciliary neurotrofic factor                | NM_170786.2 | Mm00446373_m1 |
| Fgf2        | Fibroblast growth factor 2                | NM_008006.2 | Mm01285715_m1 |
| Gapdh       | Glyceraldehyde-3-phosphate dehydrogenase   | NM_001289726| Mm99999915_g1 |
| Gfap        | Glial fibrillary acid protein              | NM_010277.3 | Mm01253033_m1 |
| IL-18       | Interleukin 18                             | NM_008360.1 | Mm00434226_m1 |
| IL-1b       | Interleukin 1-beta                         | NM_008361   | Mm00434228_m1 |
| Nlrp3       | NLR Pyrin Domain Family 3                 | NM_145827   | Mm00840904_m1 |
| Serping1    | Serine peptidase inhibitor member 1       | NM_009776   | Mm00437834_m1 |
antibody-peroxidase conjugate was used for visualisation (Bio-Rad). The protein was visualised with chemiluminescence using a Clarity Western ECL kit (Bio-Rad) and images were captured and analysed using a Chemidoc MP with Image Lab software (Bio-Rad). The expression of the protein of interest was normalised to GAPDH.

Statistical analysis
All statistical analysis was performed using Prism 6 (GraphPad Software, CA, USA). Unpaired student t-test, one-way analysis of variance (ANOVA) or two-way ANOVA were run as appropriate for each dataset. Multiple comparisons were run with appropriate post-hoc tests to determine statistical significance for the interactions between each experimental group (P < 0.05). Graphs are displayed as mean ± SEM.

Results

C1qa gene expression following photo-oxidative damage
The expression of C1qa in the murine retina was studied across the time course of photo-oxidative damage (1, 3, 5 and 7 days of photo-oxidative damage) in wild-type (WT) mice using qPCR (Fig. 1). Retinal C1qa gene expression was upregulated in the retina during the course of photo-oxidative damage, compared to dim-reared control retinas (Fig. 1a). C1qa expression was significantly elevated at 5 and 7 days (P < 0.05, Fig. 1a), but not at 1 or 3 days of photo-oxidative damage. Temporal expression of C1qa in the retina coincided with the focal loss of photoreceptors (TUNEL+ cells) in the ONL (Fig. 1b-f, arrows). TUNEL+ photoreceptor cell death reached peak numbers at 7 days of photo-oxidative damage (P < 0.05, Fig. 1a, f). Temporal expression of retinal C1qa also correlated with IBA1+ microglia/macrophage recruitment to the ONL and subretinal space of the outer retina, peaking at 5 days photo-oxidative damage (Fig. 1g-l), with significance detected at both 5 and 7 days for both C1qa expression and IBA1+ cell recruitment (P < 0.05, Fig. 1g-l). Double-labelling with CD68, a lysosomal protein, demonstrated a phagocytic phenotype of IBA1+ macrophages in the subretinal space after photo-oxidative damage (Fig. 1m). After 7 days of photo-oxidative damage, the IBA1+ macrophages were highly immunoreactive for CD68; the majority of the subretinal population contained multiple CD68+ cellular compartments (Fig. 1m). Double-labelling of TUNEL and IBA1 demonstrated that IBA1+ macrophages were in close proximity and direct contact with multiple TUNEL+ apoptotic cells in the subretinal space and ONL at 7 days of photo-oxidative damage (Fig. 1n).

Effect of C1qa knockout on the retina
Classical complement pathway knockout mice (C1qa−/−) and WT were exposed to photo-oxidative damage to assess independently the functional significance of C1qa (classical pathway) on retinal degeneration. To control for any underlying effects, we thoroughly assessed C1qa−/− mice raised in low light conditions for any histopathological or physiological changes, compared to WT (Additional file 1: Figure S1). There were no significant differences in the amplitude of a-wave, b-wave and cone responses in the C1qa−/− mice compared to WT. There was no significant change in the expression of neurotrophic factor Cntf and the stress marker Gfap. A reduction in expression was detected in Fgf2 in C1qa−/− retinas (P < 0.05, Additional file 1: Figure S1).

C1qa−/− after 7 days of photo-oxidative damage
After 7 days of photo-oxidative damage similar levels of photoreceptor death, indicated by numbers of TUNEL+ cells, were observed in C1qa−/− and WT retinas (P > 0.05, Fig. 2b-d). Measures of retinal morphologies including thickness of the photoreceptor layer at the focal lesion spot and towards the lesion edge were comparable (P > 0.05, Fig. 2e-i). Numbers of IBA1+ macrophages found in the outer retina of C1qa−/− and WT animals were also comparable following 7 days of photo-oxidative damage (P > 0.05, Fig. 2g-i). Western blots for complement C3d protein showed an increase in retinal C3d protein following 7 days of photo-oxidative damage compared to dim-reared controls (P < 0.05, Additional file 2: Figure S2). However, we showed no difference in the abundance of C3d protein in C1qa−/− retina and WT at 7 days of photo-oxidative damage (Fig. 2j); C3d protein expression, normalised to the loading control, did not significantly change in C1qa−/− and WT (P > 0.05, Fig. 2k).

ERG analysis showed no differences in a-wave, b-wave, or cone responses in C1qa−/− mice compared to WT (P > 0.05, Fig. 2l-n). Expression of complement genes in the classical pathway (C2, C4a, Serping1), however, were significantly lower in C1qa−/− retinas compared to WT (P < 0.05, Fig. 2o). Cfh expression (alternative pathway) was significantly elevated in C1qa−/− retinas at 7 days of photo-oxidative damage (P < 0.05, Fig. 2o), however, there was no significant change in the expression of Cfb. Using a photo-oxidative damage model, we have previously shown that these complement genes are upregulated in the retina following photo-oxidative damage compared to dim-reared controls [11].

The effect of C1qa knockout: Extended time course
To assess an effect of the classical pathway on photoreceptor damage beyond the standard 7-day photo-oxidative damage time course, the impact of C1qa gene ablation over an extended period after photo-oxidative damage was determined (days 8-14, Fig. 3a). Retinal expression of C1qa was significantly elevated in WT mice between day 8 (one day after the end of photo-oxidative damage) and day 14.
and accompanied by elevated levels of TUNEL+ photoreceptor cell death (P < 0.05, Fig. 3b). Photoreceptor cell death was significantly reduced in the C1qa−/− compared to WT at day 14 (P < 0.05, Fig. 3c, d), and the ONL was significantly thicker (P < 0.05, Fig. 3e).

The ONL of the superior retina in C1qa−/− mice was better preserved at the lesion site (0.5 mm) and at 1.0 mm away from the optic disc at day 14, indicated by the presence of significantly more rows of photoreceptors in the ONL compared to WT (P < 0.05, Fig. 3f).

The retinal macrophage response in C1qa−/− mice was attenuated at day 14 (Fig. 3g-h). Fewer IBA1+ macrophages were present in the ONL of C1qa−/− at day 14 compared to WT (Fig. 3g), and the numbers of IBA1+ macrophages infiltrating the ONL and subretinal space were significantly less than WT (P < 0.05, Fig. 3h).

Western blots of complement C3d in C1qa−/− and WT retina showed no difference in the abundance of complement C3d deposition in C1qa−/− retina compared to WT at day 14 (P > 0.05, Fig. 3i-j).

ERG analyses showed clear differences in retinal function at day 14 between C1qa−/− and WT (P < 0.05, Fig. 3k-n). The a-wave response and b-wave response amplitudes to flash intensities ≥0.6 log cd.s/m² were significantly greater in C1qa−/− retina compared to WT (P < 0.05, Fig. 3k, l). Differences in ERG response characteristics between C1qa−/− and WT were significant across increasing flash intensities, with the most pronounced differences observed at 1.9 log cd.s/m² (P < 0.05, Fig. 3m). There were no differences in the cone responses between the two groups (P > 0.05, Fig. 3n). Comparison of ERG responses at day 7 of photo-oxidative damage (PD) showed no differences in retinal function between C1qa−/− and WT (P > 0.05, Fig. 3o-p).
damage and day 14 (7 days after photo-oxidative damage) indicate improved retinal function in C1qa<sup>−/−</sup> animals at 14 days (P < 0.05, Fig. 3o). At day 14, C1qa<sup>−/−</sup> retina had significantly better a-wave responses (~100 μV) and b-wave responses (~200 μV) than WT at 1.9 log cd.s/m² (P < 0.05, Fig. 3o). At day 14, even at low flash intensities, the a-wave amplitudes in C1qa<sup>−/−</sup> retinas were significantly greater than in WT retinas (Fig. 3o).

**Intravitreal C1q inhibition using ANX-M1 anti-C1q antibody**

To determine whether local inhibition of C1 activation could mitigate the progression in retinal atrophy, we used an antibody against C1q (anti-C1q; ANX-M1, Annexon Biosciences), to block the classical complement cascade. Intravitreal ANX-M1, but not its immunoglobulin G (IgG) isotype control, administered immediately after the 7-day...
Fig. 3 Wild-type (WT) and C1qa<sup>−/−</sup> retina at day 14 (7 days after the end of photo-oxidative damage, PD) (a). b C1qa expression was significantly elevated in WT PD animals compared to WT dim-reared controls between day 8 and day 14, and the expression level decreased across the days of recovery, in concert with TUNEL<sup>+</sup> photoreceptor cell death (P < 0.05). c-d TUNEL<sup>+</sup> cells were present in the outer nuclear layer (ONL) of C1qa<sup>−/−</sup> and WT retinas, although the rate of cell death was significantly lower in C1qa<sup>−/−</sup> retinas (P < 0.05). e-f Photoreceptor row counts were significantly higher in C1qa<sup>−/−</sup> compared to WT, in the superior retina (0.5 mm-1.0 mm away from the optic nerve) (P < 0.05). g-h Fewer IBA1<sup>+</sup> cells were found in the ONL of C1qa<sup>−/−</sup> retinas compared to WT, and was statistically significant (P < 0.05). i-j Western blots showed that there was no significant difference in the relative intensity of C3d proteins between C1qa<sup>−/−</sup> and WT retinas, although the rate of cell death was significantly lower in C1qa<sup>−/−</sup> retinas (P < 0.05). e-f Photoreceptor row counts were significantly higher in C1qa<sup>−/−</sup> compared to WT, in the superior retina (0.5 mm-1.0 mm away from the optic nerve) (P < 0.05). g-h Fewer IBA1<sup>+</sup> cells were found in the ONL of C1qa<sup>−/−</sup> retinas compared to WT, and was statistically significant (P < 0.05). i-j Western blots showed that there was no significant difference in the relative intensity of C3d proteins between C1qa<sup>−/−</sup> and WT retinas (P < 0.05). k-l There was a stronger a-wave and b-wave responses in C1qa<sup>−/−</sup> animals compared to WT, particularly at higher flash intensities (P < 0.05). m At the highest flash intensity, C1qa<sup>−/−</sup> animals had significantly higher a-wave and b-wave amplitudes compared to WT (P < 0.05). n Cone responses were not significantly different in C1qa<sup>−/−</sup> and WT animals (P > 0.05). o Comparison of a-wave and b-wave responses at day 7 and 14 showed significantly higher amplitudes in C1qa<sup>−/−</sup> retina at day 14. Statistical significance was measured using student t-test and two-way ANOVA followed by post-hoc multiple comparison (N = 6 per group; * represents P < 0.05; NS represents no significance). For representative images, scale bars represent 50 μm.
photo-oxidative damage procedure (day 7), protected the photoreceptors against continuous degeneration at day 14 (Fig. 4). Post-damage, ANX-M1 significantly reduced the number of TUNEL+ cells in retinas at day 14, compared to IgG control antibody ($P < 0.05$; Fig. 4b). Comparison of retinal thickness showed that the ONL was significantly thicker ($P < 0.05$; Fig. 4c) in the ANX-M1 group. Negligible effects on the number of IBA1+ microglia/macrophages in the outer retinal space and ONL were observed in mice treated with anti-C1q antibody, compared to IgG control ($P > 0.05$; Fig. 4d). ERG analyses showed that the response characteristics for rod a-wave and b-wave were significantly better in the ANX-M1 treated animals ($P < 0.05$; Fig. 4e, f), with the ANX-M1 cohort demonstrating significantly higher amplitudes (a- and b-wave) at the highest flash intensities compared to IgG controls ($P < 0.05$; Fig. 4g). Cone responses were also significantly higher in the post-treatment ANX-M1 groups ($P < 0.05$; Fig. 4h).

Fig. 4 Post-treatment with local neutralisation of C1q and assessment of the retina at day 14 (a). b Post-treatment with anti-C1q monoclonal antibody (mAb), ANX-M1, immediately after 7 days of photo-oxidative damage (PD, day 7) reduced the number of TUNEL+ cells at 7 days of post damage (day 14), versus IgG control at day 14 ($P < 0.05$). c There was a significant reduction in photoreceptor loss in mice treated with ANX-M1 anti-C1q antibody ($P < 0.05$). d There was minimal effect on the IBA1+ microglia/macrophages in ANX-M1 anti-C1q antibody cohort compared to IgG control antibody ($P > 0.05$). e-g Post-treatment of retina with ANX-M1 anti-C1q antibody displayed a larger a-wave (e) and b-wave (f) compared to IgG control cohort, which was most pronounced at 1.9 log cd.s/m² (g), indicating a significantly improved retinal function ($P < 0.05$). h Cone response demonstrated a significant improvement in ANX-M1 anti-C1q antibody cohort, compared to IgG control ($P < 0.05$). Statistical analyses were determined by an unpaired student t-test or two-way ANOVA followed by post-hoc multiple comparison (* denotes $P < 0.05$; NS denotes no significance)
ANX-M1 administered before photo-oxidative damage showed no functional or morphological protection from damage in the retinas at day 14 compared to isotype control (Fig. 5). Retinal morphology (Fig. 5b-c), IBA1+ microglia/macrophage numbers (Fig. 5d) and ERGs (Fig. 5e-h) showed no significant differences between the treatment groups (P > 0.05; Fig. 5b-h), indicating that pre-damage treatment via intravitreal injection to neutralise C1q was ineffective.

**Systemic C1q inhibition using ANX-M1 anti-C1q antibody**

The results from animals treated systemically are presented in Fig. 6. A hemolytic assay using mouse serum from ANX-M1-treated and control mice showed that by day 12, serum complement activity was reduced by >50% compared to the IgG control group, following the systemic delivery paradigm of ANX-M1 anti-C1q antibody (P < 0.05; Fig. 6b).

The impact of systemic C1q neutralisation on retinal morphology was not significant. No differences in the number of TUNEL+ cells, ONL thickness or IBA1+ microglia/macrophage numbers were observed in mice treated systemically with the ANX-M1 anti-C1q antibody (P > 0.05; Fig. 6c-e). Similarly, there were no significant functional differences in a-wave, b-wave or cone response at day 12, between the ANX-M1 anti-C1q antibody and IgG control antibody groups (P > 0.05; Fig. 6f-i).

**Inflammasome expression in C1qa−/− mice**

To further assess the potential mechanism involved in modulation of the retinal inflammation observed in C1qa−/− mice, we investigated the role of inflammasome activation in photo-oxidative damage. C1q is known to activate NLRP3 inflammasome and production of IL-1β in mouse bone-marrow derived macrophages (BMDMs) primed with carboxyethylpyrrole adducts (CEP), which activate NLRP3 inflammasome and production of IL-1β.

Inflammasome expression in C1qa−/− mice were assessed in C1qa−/− and WT retinas at 7 days of photo-oxidative damage, using qPCR. Nlrp3, Casp-1 and Casp-8 expression were significantly decreased in retinas of C1qa−/− mice compared to WT at 7 days of photo-oxidative damage (P < 0.05, Fig. 7f). Additionally, expression of the pro-inflammatory cytokine genes Il-1β and Il-18 were also significantly lower in C1qa−/− mice compared to WT (~1500%, Il-1β; ~800%, Il-18; P < 0.05, Fig. 7f).

FACS isolation was used to analyse expression of inflammasome-related genes in retinal CD11b+ cells, isolated from C1qa−/− and WT mice following photo-oxidative damage (Fig. 7g). Primary myeloid cells from C1qa−/− retinas had a significantly reduced expression of Il-1β and Casp-1 compared to WT retinas (P < 0.05, Fig. 7g), but there was no detectable change in the expression of Il-18, Casp-8 or Nlrp3 (P > 0.05, Fig. 7g).

The presence of IL-1β protein in C1qa−/− and WT retinas was used to confirm inflammasome expression at 7 days of photo-oxidative damage (day 7; Fig. 7h-i) and post-damage (day 14; Fig. 7j-k) using Western blot. There was no significant difference in the abundance of IL-1β proteins observed, between C1qa−/− and WT retinas at day 7 (P > 0.05, Fig. 7i). At day 14 post-photo-oxidative damage, the IL-1β protein band in C1qa−/− retinas was significantly less intense compared to retinas from WT mice (P < 0.05, Fig. 7k).

**Localisation of C1q in mouse and human AMD donor retinas**

In dim-reared mouse retinas (Fig. 8a-i), C1q protein or F4/80+ macrophages were not detected (Fig. 8a). In photo-oxidative damaged mouse retinas, C1q protein was co-localised with amoeboid, F4/80+ macrophages at the focal retinal lesion (Fig. 8b-d) and at the edges of the photoreceptor lesion (Fig. 8e-g). Negative controls showed no specific staining for either C1q or F4/80 in the mouse retinal sections (Fig. 8h). Absence of C1q immunoreactivity was confirmed in F4/80+ macrophages in the outer retina after 7 days of photo-oxidative damage in C1qa−/− mice (Fig. 8i). Immunohistochemistry for the C1q protein in normal retina and AMD-affected retinas (Fig. 8j-r) showed no C1q-expressing cells in the normal retina (Fig. 8i). In the AMD-affected retinas, C1q proteins were detected adjacent to subretinal drusen (Fig. 8k), and in the subretinal space at the lesion edges (Fig. 8l-n). Double immunolabelling demonstrated that most of C1q-expressing cells were immunoreactive for macrophage/microglia marker IBA1 (Fig. 8o-q). Negative controls showed no specific staining for C1q or IBA1 in the human AMD section (Fig. 8r).

**Discussion**

This study investigated the contribution of C1q and the classical complement pathway in the timing of disease progression induced in retinal degeneration. Our data...
illustrate the role of locally-derived retinal C1q in driving the progression of retinal atrophy and the possibility of therapeutic interventions using C1q neutralisation. The findings indicate that: First, genetic ablation of C1qa indicated variable and inconclusive effects on retinal function during the 7 days of photo-oxidative damage. At 1 week following photo-oxidative damage (day 14), the absence of C1q was found to protect retinal structure, reduce photoreceptor cell death and inflammation, and improve retinal function. Second, we demonstrate a possible role for the classical complement pathway in the activation of the NLRP3 inflammasome and secretion of IL-1β in the degenerating retina, which may promote retinal damage during this post-exposure period. Third, by comparing neutralization of classical complement activator C1q systemically and locally in the retina, we demonstrate that local C1q expressed by subretinal microglia/
macrophages, and not serum complement, plays a vital role in the progression of retinal degeneration. Together, the results indicate that the classical complement pathway, mediated by C1q, contributes to progression of retinal degeneration. These results further indicate that a therapeutic approach targeting the classical complement initiator C1q may be beneficial in slowing the progression of focal retinal degenerations, where dysregulated

Fig. 6 Neutralisation of systemic classical complement using ANX-M1 anti-C1q antibody during the time course of photo-oxidative damage (PD) and assessment of the retina at day 12 (a). b Complement activity in the serum was inhibited (>50% less) in mice treated with ANX-M1 anti-C1q antibody compared to IgG control as examined in the hemolytic assay using sheep red blood cells ($P < 0.05$). c-e There was no difference in the number of TUNEL+ cells (c), ONL thickness (d) and IBA1+ microglia/macrophages (e) observed between the ANX-M1 anti-C1q antibody cohort and IgG control cohort ($P > 0.05$). f-h Inhibition of systemic classical complement did not change retinal function, as evident in no significant difference in a-wave (f), b-wave (g) response characteristics and mean amplitudes at highest flash intensities between the two cohorts (h) ($P > 0.05$). I No significant change in cone response was detected between the two cohorts ($P > 0.05$). Statistical analyses were determined by an unpaired student t-test or two-way ANOVA followed by post-hoc multiple comparison (*denotes $P < 0.05$; NS denotes no significance).
Fig. 7 Inflammasome activation in wild-type (WT) and C1qa<sup>−/−</sup> retinas. a-b NLRP3-expressing cells (green) localised with subretinal macrophages expressing F4/80 (red) in the subretinal space both at the lesion site and lesion edges at 7 days of photo-oxidative damage (PD). c NLRP3-expressing subretinal macrophages had NLRP3-immunopositive and bisbenzimide (BBZ)-immunopositive nuclei, confirming its localisation within the cell. d In the retina of C1qa<sup>−/−</sup> mice, there were no NLRP3-expressing cells co-localising with F4/80<sup>+</sup> macrophages. e Negative control omitting the primary antibodies displayed no specific staining for either NLRP3 or F4/80. f C1qa<sup>−/−</sup> retina showed significantly reduced expression of inflammasome-related genes compared to WT following PD (P < 0.05). g Primary myeloid cells (CD11b<sup>+</sup>) isolated from C1qa<sup>−/−</sup> retina by FACS had significantly reduced expression of IL-1β and Casp-1 (P < 0.05), but not IL-18, Nlrp3 or Casp-8 (P > 0.05). h-i Western blots for IL-1β proteins at day 7 showed similar abundance of IL-1β proteins in C1qa<sup>−/−</sup> and WT retinas; there was no significant change in the relative intensity of IL-1β protein bands between C1qa<sup>−/−</sup> and WT retinas (P > 0.05). j-k At day 14, there was significantly less abundance of IL-1β proteins in C1qa<sup>−/−</sup> retinas, compared to WT, as confirmed by densitometry (P < 0.05). Statistical analyses were performed using student t-test and one-way ANOVA followed by post-hoc multiple comparison (N = 4 per group; * represents P < 0.05; NS represents no significance). For representative images, scale bars represent 50 μm.
complement is a major feature of disease pathogenesis, such as AMD.

**The classical pathway in retinal atrophy**

C1q is associated with pathological features of age-related neurodegenerative diseases such as amyloid-β accumulation in Alzheimer’s Disease (AD), glaucomatous damage in a model of glaucoma and drusen deposition in AMD [37–39]. Evidence from other studies indicates that non-canonical functions of C1q influence local inflammation in the central nervous system (CNS), such as by promoting the dynamic shift of astrocytes to a more pro-inflammatory state which is associated with AD and Huntington’s Disease [40]. Moreover, C1q is involved in the elimination of synapses in a mouse model of AD, and blockade of C1q significantly preserved synaptic function [41, 42]. The ablation of C1qa further prevented the progressive loss of retinal ganglion cells in a mouse model of glaucoma [43]. However, a recent study demonstrated that numerous complement components, including C1q, were important in maintaining inner nuclear layer (INL) retinal integrity, and that the absence of C1q in the developing

---

Fig. 8 C1q localisation in the mouse retina after photo-oxidative damage (PD) and in human AMD retinas. **a** No immunoreactivity to C1q or F4/80 was detected in retinas from dim-reared/control animals. **b** At 7 days of PD, C1q+ cells were detected in the subretinal space at the lesion site. **c** At 7 days of PD, F4/80+ cells were also detected at the lesion site. **d** Co-localisation of C1q and F4/80 was observed in cells in the subretinal space at the lesion site. **e–g** At the lesion edge C1q+/F4/80+ macrophages were present in the subretinal space. **h** Negative control slide for the mouse retinal immunohistochemistry showed no specific staining for either C1q or F4/80. **i** There was no immunoreactivity for C1q protein in the retina of C1qa−/− mice at 7 days after photo-oxidative damage. **j** C1q localisation in the normal human retina. No C1q-expressing cells were detected in the normal retina. **k** C1q immunoreactivity was detected adjacent to the subretinal drusen of early AMD retinas (arrows). **l–n** At the lesion edge, C1q-expressing cells were present in the subretinal space of AMD retina where IBA1+ cells were predominant (arrows). **o** C1q+ immunoreactivity co-localised in IBA1+ macrophages. **p, q** C1q+/IBA1+ cells at higher magnification. **r** Negative control slide for human AMD immunohistochemistry showed no specific staining for either C1q or IBA1. Representative images derived from N = 3 per group. INL, inner nuclear layer; ONL, outer nuclear layer; OS/IS, outer/inner segments. Scale bars represent 10 μm in O–Q; elsewhere 50 μm.
C1q stimulation activates the NLRP3 inflammasome in photo-oxidative damage

In this study, in the absence of classical pathway activation, there was a reduced NLRP3 inflammasome expression in a specific population of cells - the subretinal microglia/macrophages. This finding is consistent with previous studies showing that C1q can activate NLRP3 in BMDMs of humans, and in mice after immunization with CEP-adducted mouse serum albumin, to model a dry AMD-like pathology [21]. Other evidence has demonstrated the capability of RPE cells to induce NLRP3 inflammasome expression and propagate photoreceptor toxicity in the presence of blue-light photo-oxidative damage [48].

Complement-expressing macrophages as potent local mediators of onset and progression of retinal atrophy

Retinal microglia/macrophages express complement components in rodent retinas in response to aging [31]. Here, we demonstrate that subretinal microglia/macrophages also express C1q in focal retinal degeneration. Our data show that subretinal microglia/macrophages in the degenerating retina can express CD68° lysosomal protein aggregates, and contain multiple TUNEL’ apoptotic cells, demonstrating a phagocytic phenotype. It is likely that C1q expression may be found in these phagocytic macrophages of the subretinal space, as we have detected C1q expression co-localising with subretinal microglia/macrophages in the degenerating retina after photo-oxidative damage. It is plausible that C1q is
secreted to bind and recognize defective synapses at a stage of disease prior to overt neurodegeneration, as reported in models of neurodegenerative diseases in the brain and retina [38, 43], however this was not observed directly in this study.

In normal and diseased brain tissues resident microglia express many-fold higher levels of $C1qa$, $b$ and $c$, the three protein subunits of C1q, compared to macrophages and other myeloid cells [53, 54]. The capacity of microglia to synthesize $C1qa$ has been confirmed in rodent brain [55], however, in the context of AMD the close interdependence and proximity of the retina with Bruch’s membrane/RPE/choroid confounds the argument that microglia are the key synthesizers of C1q. Our findings demonstrate that C1q proteins are localised near drusen and in the subretinal microglia/macrophages of human AMD patients whose RPE atrophy was prominent. The delayed appearance of these C1q-expressing subretinal microglia/macrophages, coincides with RPE and choriorcapillaris breakdown [56] suggesting a population derived from the choriorcapillaris. However, a recent study investigating models of RPE breakdown suggests that subretinal populations are predominantly resident microglia, owing to their rapid mobilisation from the inner retina to the site of injury [57].

Our findings with the local delivery of the C1q neutralisation suggest that locally-derived C1q contributes to the progression of retinal atrophy. Coupled with the association of C1q expressed by myeloid cells with neuroinflammation and age-related neurodegeneration [58], our findings support the idea that locally administered immunotherapy targeting the classical complement pathway may be effective in slowing the progression of retinal degeneration. We did not detect any ocular inflammation specifically associated with anti-C1q delivery in these experiments. This suggests that administration of an anti-C1q antibody is unlikely to have additional risks to those normally associated with intravitreal injections (reviewed in [59]). Further investigations are required to explore the mechanisms underlying the protective effect of local C1q neutralisation.

Conclusions

This study illustrates the contribution of the classical complement pathway in facilitating retinal atrophy induced by photo-oxidative damage. The classical pathway, through its initiating molecule C1q, appears to exacerbate photoreceptor damage through interaction with the inflammasome. The efficacy of intravitreal C1q-targeted inhibition in ameliorating the late-stage of photo-oxidative damage-induced retinal atrophy, reinforces the concept that targeting C1q, or the macrophage capability to express complement, may be effective in slowing the progression of retinal degenerations. Further utilisation of strategies that can elucidate the exact origins of complement-expressing macrophages - microglia or monocytes - are warranted. Clarifying the identity and function of these complement-expressing myeloid cells will enable the design of more precise therapeutics targeting the complement system, which may be beneficial for retinal diseases where macrophage recruitment and complement activation are a key pathogenic feature, including AMD.

Additional files

Additional file 1: Figure S1. Characterisation of dim-reared C57BL/6 J wild-type (WT) and $C1qa^{-/-}$ mouse retinas. A-C: The ERG a-wave and b-wave responses also did not change significantly between WT and $C1qa^{-/-}$; cone response also displayed no difference between two groups ($P > 0.05$). D: No difference was shown in the expression of neuroprotective genes ($P > 0.05$) except for $	ext{Fgf2}$, which showed a significantly downregulation compared to WT ($P < 0.05$; $N = 5$ animals per group). Statistical significance was determined by an unpaired student t-test or two-way ANOVA with multiple comparison post hoc (* represents $P < 0.05$; NS represents no significance). (TIF 8158 kb)

Additional file 2: Figure S2. Retinal C3d protein levels in wild-type (WT) dim-reared controls and after 7 days of photo-oxidative damage (PD): A: C3d protein levels significantly increased in retinas following 7 days of photo-oxidative damage ($P < 0.05$; $N = 4$). C3d levels were normalised to a GAPDH loading control. B-C: Representative western blots showing an increased level of C3d after 7 days of photo-oxidative damage (C) compared to dim-reared controls (B). Statistical significance was determined by an unpaired student t-test (* represents $P < 0.05$). (TIF 4344 kb)

Abbreviations

ACTB: beta-actin; AD: Alzheimer’s Disease; AMD: Age-Related Macular Degeneration; ANOVA: Analysis of variance; ANU: Australian National University; ARVO: Association for Research in Vision and Ophthalmology; BB2: Bixinizemide; BMDM: Bone-marrow derived macrophage; C1q: Complement component 1q; C1qa: Complement component 1q, subcomponent alpha; C1s: Complement component 1 s; C2: Complement component 2; C3d: Complement component 3d; C4: Complement component 4; CASP-1: Caspase 1; CASP-8: Caspase 8; CD11b: Cluster of differentiation molecule 11b; cDNA: Complementary DNA; CEP: Carboxyethylpyrrole; CFB: Complement factor B; CFH: Complement factor H; CFI: Complement factor I; CO$_2$: Carbon dioxide; DNA: Deoxyribonucleic acid; dUTP: 2’-Deoxyuridine 5’-triphosphate; ERG: Electroretinography; FACS: Fluorescence-activated cell sorting; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; GWAS: Genome-wide association studies; I/R: Ischemia/reperfusion; IBA-1: Ionised calcium binding adapter molecule 1; IgG: Immunoglobulin G; IL-1β: Interleukin 1β; IL-18: Interleukin 18; IVC: Individual wave responses also did not change significantly between WT and $C1qa^{-/-}$; cone response also displayed no difference between two groups ($P > 0.05$); SERPING1: Serpin family G member 1; TUNEL: Terminal deoxynucleotidyl transferase (TdT) dUTP nick end labelling; WT: Wild-type; ΔΔCt: Comparative cycle threshold

Acknowledgments

The authors thank the NSW Organ and Tissue Donation Service. The authors also thank Annexon Bioscience (San Francisco, CA, USA) for their C1q neutralizing antibodies.
**Ethical approval**
All experiments were conducted in accordance with the ARVO Statement for Use of Animals in Ophthalmic and Vision Research, and had approval from the Australian National University (ANU) Animal Experimentation Ethics Committee (Ethics ID: A2014/56 and A2017/41).

**Funding**
This research was supported by an Australian Government Research Training Program (RTP) Scholarship.

**Availability of data and materials**
All data generated or analysed during this study are included in this published article.

**Authors’ contributions**
HI designed and performed in vivo procedures, conducted the experiments, analysed the data, performed statistical analysis, prepared the figures and the draft manuscript. MR, NF, RA, ans JP were all involved in the design, and contributed to the production of the final manuscript. TY and SS were involved in the C1q neutralisation experiments and provided key technical information, while RN was responsible for all aspects of the project and compiling of the final manuscript. All authors read and approved the final manuscript.

**Consent for publication**
Not applicable.

**Competing interests**
Ted Vedinock and Sethu Sankaranarayan are both affiliated with Annexon Biosciences. All other authors declare that they have no competing interests.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**
1The John Curtin School of Medical Research, The Australian National University, Building 131, Garran Rd, Canberra, ACT 2601, Australia.
2Department of Anatomy and Neuroscience, The University of Melbourne, Parkville, VIC, Australia. 3Annexon Biosciences, South San Francisco, CA, USA. 4ANU Medical School, The Australian National University, ACT, Canberra, Australia.

**Received:** 4 June 2018 **Accepted:** 13 August 2018 **Published online:** 20 August 2018

**References**
1. Walport MJ. Advances in immunology: complement (first of two parts). New Engl J Med. 2001;344(14):1058–66.
2. Nauta AJ, Trouw LA, Daha MR, Tijsma O, Nieuwland R, Schwaeble WJ, et al. Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. Eur J Immunol. 2002;32(6):1726–36.
3. Chikazawa M, Shibata T, Hatasa Y, Hirose S, Otaki N, Nakashima F, et al. Identification of C1q as a binding protein for advanced glycation end products. Biochemistry-US. 2016;55(3):435–46.
4. Gasque P. Complement: a unique innate immune sensor for danger signals. Mol Immunol. 2004;41(11):1089–98.
5. Ambati J, Aitkinson JP, Gelfand BD. Immunology of age-related macular degeneration. Nat Rev Immunol. 2013;13(6):438–51.
6. Khandhadia S, Cipriani V, Yates JRW, Lottery AJ. Age-related macular degeneration and the complement system. Immunobiology. 2012;217(2):127–46.
7. Anderson DH, Radeke MJ, Gallo NB, Chapin EA, Johnson PT, Curlety CR, et al. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res. 2010;29(2):95–112.
8. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adams WP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 2003;48(3):257–93.
9. Newman AM, Gallo NB, Hancox LS, Miller NJ, Radeke CM, Maloney MA, et al. Systems-level analysis of age-related macular degeneration reveals global biomarkers and phenotype-specific functional networks. Genome Medicine. 2012;4(2):1–18.
10. Penfold PL, Madigan MC, Gillies MC, Provis JM. Immunological and aetiological aspects of macular degeneration. Prog Retin Eye Res. 2001;20(3):385–414.
11. Natoli R, Fernando N, Jiao HH, Rasic T, Madigan M, Barnett NL, et al. Retinal macrophages synthesize C3 and activate complement in AMD and in models of focal retinal degeneration. Invest Ophth Vis Sci. 2017;58(7):2997–90.
12. Rutar M, Natoli R, Kozulin P, Valter K, Gatenby P, Provis JM. Analysis of complement expression in light-induced retinal degeneration: synthesis and deposition of C3 by microglia/macrophages is associated with focal photoreceptor degeneration. Invest Ophthalomol Vis Sci. 2011;52(8):5347–58.
13. Mullins RF, Warwick AN, Sohn EH, Lottery AJ. From compliment to insult: genetics of the complement system in physiology and disease in the human retina. Hum Mol Genet. 2017;26(1):R51–7.
14. Xu H, Chen M. Targeting the complement system for the management of retinal inflammatory and degenerative diseases. Eur J Pharmacol. 2016;787:104.
15. Roehrer B, Coughlin B, Kunchithapatham K, Long Q, Tomlinson S, Takahashi K, et al. The alternative pathway is required, but not alone sufficient, for retinal pathology in mouse laser-induced choroidal neovascularization. Mol Immunol. 2011;48(6):e1–8.
16. Tan PL, Boxows Rickman C, Katsaris N. AMD and the alternative complement pathway: genetics and functional implications. Human genetics. 2016;10(1):23.
17. Gold B, Merriam JE, Zemrant J, Hancox LS, Taibler AJ, Gehrs K, et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet. 2006;38(4):458–62.
18. Gu XR, Meer SG, Miyagi M, Rayborn ME, Hollenberg JG, Grabb JW, et al. Carboxylated lipoprotein adducts and autoantibodies, biomarkers for age-related macular degeneration. J Biol Chem. 2003;278(42):40273–35.
19. Patel N, Ohbayashi M, Nugent AK, Kuchta M, Toda T, Chau KY, et al. Circulating anti-retinal antibodies as immune markers in age-related macular degeneration. Immunology. 2005;115(3):422–30.
20. Penfold PL, Provis JM, Furby JH, Gatenby PA, Billson FA. Autoantibodies to retinal astrocytes associated with age-related macular degeneration. Graef Arch Clin Exp. 1990;228(3):270–4.
21. Doyle SL, Campbell M, Otsuki E, Solomon RG, Mori A, Kenna PF, et al. NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. Nat Med. 2012;18(5):791–U191.
22. Dunkelberger JR, Song W-C. Complement and its role in innate and adaptive immune responses. Cell Res. 2009;20(1):34–50.
23. Toapanta FR, Ross TM. Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immune systems. Cell Res. 2009;20(1):34–50.
24. Silverman SM, Kim BJ, Howell GR, Miller J, John SWM, Wordinger RJ, et al. C1q propagates microbial activation and neurodegeneration in the visual axis following retinal ischemia/reperfusion injury. Mol Neurodegener. 2016;11.
25. Fernando N, Natoli R, Valter K, Provis J, Rutar M. The broad-spectrum chemokine inhibitor NR88-3.14.3 modulates macrophage-mediated inflammation in the diseased retina. J Neuroinflammation. 2016;13(1):47.
26. Rutar M, Natoli R, Provis JM. Small interfering RNA-mediated suppression of C3d in Müller cells attenuates microbial recruitment and photoreceptor death following retinal degeneration. J Neuroinflammation. 2012;9:221.
27. Fernando N, Natoli R, Rasic T, Woolf Y, Provis J, Valter K. The use of the vaccinia virus complement control protein (VCP) in the rat retina. PLoS One. 2018;13(3):e0193740.
28. Maslim J, Valter K, Egensperger R, Holländer H, Stone J. Tissue oxygen regulation underlying photoreceptor protection: microarray study of dietary antioxidant saffron and photobiomodulation in rat retina. Mol Vis. 2010;16:1801–22.
29. Rutar M, Natoli R, Chia R, Valter K, Provis J. Chemokine-mediated inflammation in the degenerating retina is coordinated by Müller cells, activated microglia, and retinal pigment epithelium. J Neuroinflammation. 2015;12(1):28.
31. Ma W, Cojocaru R, Gotoh N, Gieser L, Villasmit R, Cogliati T, et al. Gene expression changes in aging retinal microglia: relationship to microglial support functions and regulation of activation. Neurobiol Aging. 2013;34(10):2310–21.

32. Naloti R, Provìs J, Valter K, Stone J. Gene regulation induced in the C57BL/6J mouse retina by hyperoxia: a temporal microarray study. Mol Vis. 2008;14:1983.

33. Rutar M, Naloti R, Valter K, Provìs JM. Early focal expression of the chemokine Ccl2 by Muller cells during exposure to damage-inducing bright continuous light. Invest Ophthalmo Vis Sci. 2011;52(5):2379–88.

34. Walker RJ, Steineki JJ. Role of beta-adrenergic receptors in inflammatory marker expression in Muller cells. Invest Ophthalmo Vis Sci. 2007;48(11):5276–81.

35. Stasi K, Nagel D, Yang XY, Wang RF, Ren LZ, Pods SM, et al. Complement component 1Q (C1Q) upregulation in retina of murine, primate, and human, and glaucomatous eyes. Invest Ophthal Vis Sci. 2006;47(3):1024–9.

36. Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, et al. Cell-specific deletion of C1qa identifies microglia as the dominant source of C1q in mouse brain. J Neuroinflamm. 2017;14.

37. Bennett ML, Bennett FC, Liddelow SA, Ajami B, Zamanian JL, Fernhoff NB, et al. New tools for studying microglia in the mouse and human CNS. P Natl Acad Sci USA. 2016;113(12):E1738–46.

38. Biesemeier A, Taubitz T, Julien S, Yoneuek E, Scharpfmeyer U. Choroidocapillary breakdown precedes retinal degeneration in age-related macular degeneration. Neurobiol Aging. 2014;35(11):2562–73.

39. Ma WX, Zhang YK, Gao C, Farris RN, Tam J, Wong WT. Monocyte infiltration and proliferation reestablish myeloid cell homeostasis in the mouse retina following retinal pigment epithelial cell injury. Sci Rep-Uk. 2017;7.

40. Harvey H, Duratt S. The role of glial cells and the complement system in retinal diseases and Alzheimer's disease: common neural degeneration mechanisms. Exp Brain Res. 2014;252(11):3363–77.

41. Ghaseiri Jafarvar E, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye. 2013;27:878.